Skip to main navigation Skip to search Skip to main content

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

  • Matteo Santoni
  • , Giandomenico Roviello
  • , Enrique Grande
  • , Ugo De Giorgi
  • , Ondrej Fiala
  • , Emmanuel Seront
  • , Javier Molina-Cerrillo
  • , Renate Pichler
  • , Zin W. Myint
  • , Jakub Kucharz
  • , Ravindran Kanesvaran
  • , Thomas Büttner
  • , Martin Pichler
  • , Umberto Basso
  • , Jindrich Kopecky
  • , Maria T. Bourlon
  • , Linda Cerbone
  • , Tomas Buchler
  • , Alvaro Pinto
  • , Alfonso Gómez de Liaño
    • Caterina Gianni, Anca Zgura, Pasquale Rescigno, Jawaher Ansari, Orazio Caffo, Zsófia Küronya, Maria Giuseppa Vitale, Dipen Bhuva, Martina Catalano, Nuno Vau, Ray Manneh Kopp, Sebastiano Buti, Aristotelis Bamias, Camillo Porta, Kaisa Sunela, Francesco Massari

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science